RecruitingNCT06579469

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy (PROSPER)

Sponsor

St. Jude Children's Research Hospital

Enrollment

100 participants

Start Date

Jan 20, 2026

Study Type

OBSERVATIONAL

Conditions

Solid Tumor Hematologic Malignancy B-ALL

Summary

This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.

Eligibility

Max Age: 30 Years

Inclusion Criteria3

Participants must have received an initial systemically-administered CAR T cell infusion within the last 1-3 months (+/- 14 days).
Initial infusion is defined as the first administration of a CAR T cell product the participant has not previously received OR receipt of a CAR T cell product previously received after an interval allogeneic HSCT.
Age ≤ 30 years at CAR T cell infusion.

Exclusion Criteria4

Active malignancy other than the disease under study.
Planned consolidative HSCT within 3 months post CAR T cell infusion.
Received or planned additional disease directed therapy post CAR T cell infusion.
Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.